| Literature DB >> 23659858 |
David R Bauman1, Alan Whitehead, Lisa C Contino, Jisong Cui, Margarita Garcia-Calvo, Xin Gu, Nancy Kevin, Xiuying Ma, Lee-yuh Pai, Kashmira Shah, Xiaolan Shen, Sloan Stribling, Hratch J Zokian, Joe Metzger, Diane E Shevell, Sherman T Waddell.
Abstract
In an effort to understand the origin of blood-pressure lowering effects observed in recent clinical trials with 11β-HSD1 inhibitors, we examined a set of 11β-HSD1 inhibitors in a series of relevant in vitro and in vivo assays. Select 11β-HSD1 inhibitors reduced blood pressure in our preclinical models but most or all of the blood pressure lowering may be mediated by a 11β-HSD1 independent pathway.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23659858 DOI： 10.1016/j.bmcl.2013.03.011
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823